PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22267726-0 2012 Pyroglutamate amyloid beta (Abeta) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 28-33 24158021-1 2014 BACKGROUND: N-terminally truncated, pyroglutamate-modified amyloid-beta (Abeta) peptides are major constituents of amyloid deposits in Alzheimer"s disease (AD). Pyrrolidonecarboxylic Acid 36-49 amyloid beta (A4) precursor protein Mus musculus 73-78 24595198-1 2014 Pyroglutamate amyloid-beta peptides (pGlu-Abeta) are particularly pernicious forms of amyloid-beta peptides (Abeta) present in Alzheimer"s disease (AD) brains. Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 42-47 24595198-1 2014 Pyroglutamate amyloid-beta peptides (pGlu-Abeta) are particularly pernicious forms of amyloid-beta peptides (Abeta) present in Alzheimer"s disease (AD) brains. Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 109-114 24595198-2 2014 pGlu-Abeta peptides are N-terminally truncated forms of full-length Abeta peptides (flAbeta(1-40/42)) in which the N-terminal glutamate is cyclized to pyroglutamate to generate pGlu-Abeta(3-40/42). Pyrrolidonecarboxylic Acid 151-164 amyloid beta (A4) precursor protein Mus musculus 5-10 24595198-2 2014 pGlu-Abeta peptides are N-terminally truncated forms of full-length Abeta peptides (flAbeta(1-40/42)) in which the N-terminal glutamate is cyclized to pyroglutamate to generate pGlu-Abeta(3-40/42). Pyrrolidonecarboxylic Acid 151-164 amyloid beta (A4) precursor protein Mus musculus 68-73 24595198-2 2014 pGlu-Abeta peptides are N-terminally truncated forms of full-length Abeta peptides (flAbeta(1-40/42)) in which the N-terminal glutamate is cyclized to pyroglutamate to generate pGlu-Abeta(3-40/42). Pyrrolidonecarboxylic Acid 151-164 amyloid beta (A4) precursor protein Mus musculus 68-73 22267726-1 2012 Pyroglutamate-modified Abeta peptides at amino acid position three (Abeta(pE3-42)) are gaining considerable attention as potential key players in the pathogenesis of Alzheimer disease (AD). Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 23-28 22267726-1 2012 Pyroglutamate-modified Abeta peptides at amino acid position three (Abeta(pE3-42)) are gaining considerable attention as potential key players in the pathogenesis of Alzheimer disease (AD). Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 68-73 21301857-0 2011 Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Abeta deposits in hippocampus via distinct cellular mechanisms. Pyrrolidonecarboxylic Acid 69-82 amyloid beta (A4) precursor protein Mus musculus 90-95 21795681-2 2011 Using one- and two-dimensional gel electrophoresis, immunoblotting, and mass spectrometry, we identified the Abeta peptides Abeta(1-40), -(1-42), -(1-39), -(1-38), -(1-37), -(2-40), and -(3-40) as well as minor amounts of pyroglutamate-modified Abeta (Abeta(N3pE)) and endogenous murine Abeta in brains from 24-month-old mice. Pyrrolidonecarboxylic Acid 222-235 amyloid beta (A4) precursor protein Mus musculus 109-114 21795681-2 2011 Using one- and two-dimensional gel electrophoresis, immunoblotting, and mass spectrometry, we identified the Abeta peptides Abeta(1-40), -(1-42), -(1-39), -(1-38), -(1-37), -(2-40), and -(3-40) as well as minor amounts of pyroglutamate-modified Abeta (Abeta(N3pE)) and endogenous murine Abeta in brains from 24-month-old mice. Pyrrolidonecarboxylic Acid 222-235 amyloid beta (A4) precursor protein Mus musculus 124-129 21795681-2 2011 Using one- and two-dimensional gel electrophoresis, immunoblotting, and mass spectrometry, we identified the Abeta peptides Abeta(1-40), -(1-42), -(1-39), -(1-38), -(1-37), -(2-40), and -(3-40) as well as minor amounts of pyroglutamate-modified Abeta (Abeta(N3pE)) and endogenous murine Abeta in brains from 24-month-old mice. Pyrrolidonecarboxylic Acid 222-235 amyloid beta (A4) precursor protein Mus musculus 124-129 21900558-0 2011 Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Abeta is induced by pyroglutamate-Abeta formation. Pyrrolidonecarboxylic Acid 117-130 amyloid beta (A4) precursor protein Mus musculus 97-102 21900558-0 2011 Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Abeta is induced by pyroglutamate-Abeta formation. Pyrrolidonecarboxylic Acid 117-130 amyloid beta (A4) precursor protein Mus musculus 131-136 22064070-2 2012 Among them, recent studies indicate that the pyroglutamate modification of Abeta (pE(3)Abeta) catalyzed by glutaminyl cyclase might play an important role in the pathogenesis of AD. Pyrrolidonecarboxylic Acid 45-58 amyloid beta (A4) precursor protein Mus musculus 75-92 34776512-2 2022 The Abeta peptide exists in several forms, including full-length Abeta1-42 and Abeta1-40 - and the N-truncated species, pyroglutamate Abeta3-42 and Abeta4-42, which appear to play a major role in neurodegeneration. Pyrrolidonecarboxylic Acid 120-133 amyloid beta (A4) precursor protein Mus musculus 4-9 18836460-0 2008 Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer"s disease-like pathology. Pyrrolidonecarboxylic Acid 41-54 amyloid beta (A4) precursor protein Mus musculus 55-60 18836460-1 2008 Because of their abundance, resistance to proteolysis, rapid aggregation and neurotoxicity, N-terminally truncated and, in particular, pyroglutamate (pE)-modified Abeta peptides have been suggested as being important in the initiation of pathological cascades resulting in the development of Alzheimer"s disease. Pyrrolidonecarboxylic Acid 135-148 amyloid beta (A4) precursor protein Mus musculus 163-168 18836460-1 2008 Because of their abundance, resistance to proteolysis, rapid aggregation and neurotoxicity, N-terminally truncated and, in particular, pyroglutamate (pE)-modified Abeta peptides have been suggested as being important in the initiation of pathological cascades resulting in the development of Alzheimer"s disease. Pyrrolidonecarboxylic Acid 150-152 amyloid beta (A4) precursor protein Mus musculus 163-168 19823761-1 2010 The presence of Abeta(pE3) (N-terminal truncated Abeta starting with pyroglutamate) in Alzheimer"s disease (AD) has received considerable attention since the discovery that this peptide represents a dominant fraction of Abeta peptides in senile plaques of AD brains. Pyrrolidonecarboxylic Acid 69-82 amyloid beta (A4) precursor protein Mus musculus 16-26 19545911-3 2009 In the present study we further investigated the mechanisms of toxicity of one of the most abundant N-truncated/modified Abeta peptide bearing amino-terminal pyroglutamate at position 3 (AbetaN3(pE)). Pyrrolidonecarboxylic Acid 158-171 amyloid beta (A4) precursor protein Mus musculus 121-126 34776512-4 2022 By solving crystal structures for TAP01 family antibodies bound to pyroglutamate Abeta3-14, we identified a novel pseudo beta-hairpin structure in the N-terminal region of Abeta and show that this underpins its unique binding properties. Pyrrolidonecarboxylic Acid 67-80 amyloid beta (A4) precursor protein Mus musculus 172-177 30391539-0 2019 Deceleration of the neurodegenerative phenotype in pyroglutamate-Abeta accumulating transgenic mice by oral treatment with the Abeta oligomer eliminating compound RD2. Pyrrolidonecarboxylic Acid 51-64 amyloid beta (A4) precursor protein Mus musculus 65-70 34769222-1 2021 Compelling evidence suggests that pyroglutamate-modified Abeta (pGlu3-Abeta; AbetaN3pG) peptides play a pivotal role in the development and progression of Alzheimer"s disease (AD). Pyrrolidonecarboxylic Acid 34-47 amyloid beta (A4) precursor protein Mus musculus 57-62 33848635-4 2021 We have developed a novel, high affinity antibody against Abeta peptides bearing a pyroglutamate residue at amino acid position 3 (3pE), an Abeta species abundantly present in plaque deposits in AD brains. Pyrrolidonecarboxylic Acid 83-96 amyloid beta (A4) precursor protein Mus musculus 58-63 33848635-4 2021 We have developed a novel, high affinity antibody against Abeta peptides bearing a pyroglutamate residue at amino acid position 3 (3pE), an Abeta species abundantly present in plaque deposits in AD brains. Pyrrolidonecarboxylic Acid 83-96 amyloid beta (A4) precursor protein Mus musculus 140-145 33881611-1 2021 One of the main components of senile plaques in Alzheimer"s disease (AD)-affected brain is the Abeta peptide species harboring a pyroglutamate at position three pE3-Abeta. Pyrrolidonecarboxylic Acid 129-142 amyloid beta (A4) precursor protein Mus musculus 95-100 33881611-1 2021 One of the main components of senile plaques in Alzheimer"s disease (AD)-affected brain is the Abeta peptide species harboring a pyroglutamate at position three pE3-Abeta. Pyrrolidonecarboxylic Acid 129-142 amyloid beta (A4) precursor protein Mus musculus 165-170 30391539-0 2019 Deceleration of the neurodegenerative phenotype in pyroglutamate-Abeta accumulating transgenic mice by oral treatment with the Abeta oligomer eliminating compound RD2. Pyrrolidonecarboxylic Acid 51-64 amyloid beta (A4) precursor protein Mus musculus 127-132 30391539-6 2019 Here, we report on the in vitro and in vivo efficacy of the compound towards pyroglutamate-Abeta, a particular aggressive Abeta species. Pyrrolidonecarboxylic Acid 77-90 amyloid beta (A4) precursor protein Mus musculus 91-96 30391539-6 2019 Here, we report on the in vitro and in vivo efficacy of the compound towards pyroglutamate-Abeta, a particular aggressive Abeta species. Pyrrolidonecarboxylic Acid 77-90 amyloid beta (A4) precursor protein Mus musculus 122-127 29673150-3 2018 Among these, a particularly neurotoxic and disease-specific Abeta variant is N-terminally truncated and modified to pyroglutamate (pE-Abeta). Pyrrolidonecarboxylic Acid 116-129 amyloid beta (A4) precursor protein Mus musculus 60-65 29673150-3 2018 Among these, a particularly neurotoxic and disease-specific Abeta variant is N-terminally truncated and modified to pyroglutamate (pE-Abeta). Pyrrolidonecarboxylic Acid 116-129 amyloid beta (A4) precursor protein Mus musculus 134-139 25547635-1 2015 Pyroglutamate-modified amyloid-beta (Abeta) at amino acid position three (Abeta(pE3-42)) is gaining considerable attention as a potential key player in the pathogenesis of Alzheimer"s disease (AD). Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 37-42 26697885-1 2016 Pyroglutamate-modified amyloid-beta (pE-Abeta) is a highly neurotoxic amyloid-beta (Abeta) isoform and is enriched in the brains of individuals with Alzheimer disease compared with healthy aged controls. Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 40-45 26697885-1 2016 Pyroglutamate-modified amyloid-beta (pE-Abeta) is a highly neurotoxic amyloid-beta (Abeta) isoform and is enriched in the brains of individuals with Alzheimer disease compared with healthy aged controls. Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 84-89 26697885-2 2016 Pyroglutamate formation increases the rate of Abeta oligomerization and alters the interactions of Abeta with Cu(2+) and lipids; however, a link between these properties and the toxicity of pE-Abeta peptides has not been established. Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 46-51 26697885-2 2016 Pyroglutamate formation increases the rate of Abeta oligomerization and alters the interactions of Abeta with Cu(2+) and lipids; however, a link between these properties and the toxicity of pE-Abeta peptides has not been established. Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 99-104 26697885-2 2016 Pyroglutamate formation increases the rate of Abeta oligomerization and alters the interactions of Abeta with Cu(2+) and lipids; however, a link between these properties and the toxicity of pE-Abeta peptides has not been established. Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 99-104 26697885-7 2016 Pyroglutamate formation was additionally found to increase the relative efficiency of Abeta-dityrosine oligomer formation mediated by copper-redox cycling. Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 86-91 25666182-7 2015 Also, in mouse primary astrocyte culture, a simultaneous up-regulation of isoQC and CCL2 expression was revealed upon Abeta and pGlu-Abeta stimulation. Pyrrolidonecarboxylic Acid 128-132 amyloid beta (A4) precursor protein Mus musculus 133-138 26453001-0 2015 An anti-pyroglutamate-3 Abeta vaccine reduces plaques and improves cognition in APPswe/PS1DeltaE9 mice. Pyrrolidonecarboxylic Acid 8-21 amyloid beta (A4) precursor protein Mus musculus 24-29 26453001-1 2015 Pyroglutamate-3 amyloid-beta (pGlu-3 Abeta) is an N-terminally truncated Abeta isoform likely playing a decisive role in Alzheimer"s disease pathogenesis. Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 37-42 26453001-1 2015 Pyroglutamate-3 amyloid-beta (pGlu-3 Abeta) is an N-terminally truncated Abeta isoform likely playing a decisive role in Alzheimer"s disease pathogenesis. Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 73-78 25547635-1 2015 Pyroglutamate-modified amyloid-beta (Abeta) at amino acid position three (Abeta(pE3-42)) is gaining considerable attention as a potential key player in the pathogenesis of Alzheimer"s disease (AD). Pyrrolidonecarboxylic Acid 0-13 amyloid beta (A4) precursor protein Mus musculus 74-79 25547635-6 2015 These results support a major pathological function of pyroglutamate Abeta in AD. Pyrrolidonecarboxylic Acid 55-68 amyloid beta (A4) precursor protein Mus musculus 69-74